Targeted idiotype-fusion DNA vaccines for human multiple myeloma: Preclinical testing

European Journal of Haematology

Volumn 86, Issue 5, 2011, Pages 385-395

  Frøyland, Marianne ^a   Ruffini, Pier Adelchi ^a   Thompson, Keith Michael ^a   Gedde Dahl, Tobias ^a   Fredriksen, Agnete Brunsvik ^a   Bogen, Bjarne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer vaccine; DNA vaccines; Fusion protein; Idiotype; Immunotherapy; Minimal residual disease; Multiple myeloma

Indexed keywords

DNA VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN IDIOTYPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PARAPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DNA IMMUNIZATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE AMPLIFICATION; GENETIC TRANSFECTION; IMMUNOGENICITY; IMMUNOGLOBULIN VARIABLE REGION; MINIMAL RESIDUAL DISEASE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; PROTEIN PURIFICATION; QUALITY CONTROL; REMISSION; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CANCER VACCINES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PLASMACYTOMA; REMISSION INDUCTION; VACCINES, DNA;

EID: 79954418231     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01590.x     Document Type: Article

References (41)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
2. San-Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008;26:2761-6.
3. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 1972;69:1540-4.
4. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 2002;87:989-1001.
5. Coscia M, Mariani S, Battaglio S, Di BC, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 2004;18:139-45.
6. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998;4:1281-6.
7. Savelyeva N, Munday R, Spellerberg MB, Lomonossoff GP, Stevenson FK. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol 2001;19:760-4.
8. Fredriksen AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther 2006;13:776-85.
9. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol 2007;178:4169-76.
10. Fredriksen AB, Bogen B. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood 2007;110:1797-805.
11. Forconi F, King CA, Sahota SS, Kennaway CK, Russell NH, Stevenson FK. Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. Immunology 2002;107:39-45.
12. Harousseau JL, Attal M, vet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-46.
13. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010;28:2612-24.
14. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
15. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
16. Sahota SS, Townsend M, Stevenson FK. Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma. Methods Mol Med 2005;113:105-19.
17. Thompson KM, Sletten K, Brandtzaeg P, Kallberg E, Wien TN, Husby G. Articular, monoclonal gamma3 heavy-chain deposition disease: characterization of a partially deleted heavy-chain gene and its protein product synthesized in vivo and in vitro. Arthritis Rheum 2003;48:3266-71.
18. Dooper MM, Holden L, Faeste CK, Thompson KM, Egaas E. Monoclonal antibodies against the candidate lupin allergens alpha-conglutin and beta-conglutin. Int Arch Allergy Immunol 2007;143:49-58.
19. Eidem JK, Rasmussen IB, Lunde E, Gregers TF, Rees AR, Bogen B, Sandlie I. Recombinant antibodies as carrier proteins for sub-unit vaccines: influence of mode of fusion on protein production and T-cell activation. J Immunol Methods 2000;245:119-31.
20. Winberry L, Marks A, Baumal R. Immunoglobulin production and secretion by variant clones of the MOPC 315 mouse myeloma cell line. J Immunol 1980;124:1174-82.
21. Bogen B, Ruffini PA, Corthay A, Fredriksen AB, Froyland M, Lundin K, Rosjo E, Thompson K, Massaia M. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica 2006;91:941-8.
22. Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006;98:1292-301.
23. Moshitzky S, Kukulansky T, Haimovich J, Hollander N. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin. Immunol Cell Biol 2008;86:261-7.
24. Kodama K, Ghanta VK, Hiramoto NS, Hiramoto RN. Regression of MOPC 104E plasmacytoma with monoclonal anti-idiotype antibodies. J Biol Response Mod 1989;8:385-96.
25. Manning DD, Jutila JW. Prevention of myeloma growth in BALB-c mice by injection of anti-immunoglobulin antisera. J Immunol 1974;113:78-83.
26. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol 2008;26:2895-900.
27. Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003;101:4607-10.
28. Dembic Z, Schenck K, Bogen B. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci USA 2000;97:2697-702.
29. Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 1994;91:5700-4.
30. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005;22:371-83.
31. Hong S, Qian J, Yang J, Li H, Kwak LW, Yi Q. Roles of idiotype-specific T cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res 2008;68:8456-64.
32. Cosenza H, Augustin AA, Julius MH. Idiotypes and anti-idiotypes as probes in analysis of immunoregulation. Cold Spring Harb Symp Quant Biol 1977;2:709-18.
33. Schrater AF, Goidl EA, Thorbecke GJ, Siskind GW. Production of auto-anti-idiotypic antibody during the normal immune response to TNP-ficoll. III. Absence in nu/nu mice: evidence for T-cell dependence of the anti-idiotypic-antibody response. J Exp Med 1979;150:808-17.
34. Jacobsen JT, Lunde E, Sundvold-Gjerstad V, Munthe LA, Bogen B. The cellular mechanism by which complementary Id(+) and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol 2010;88:515-22.
35. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996;26:2671-9.
36. Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B. Clonal deletion of thymocytes as a tumor escape mechanism. Int J Cancer 1998;78:216-22.
37. Bogen B, Ruffini P. Review: to what extent are T cells tolerant to immunoglobulin variable regions? Scand J Immunol 2009;70:526-30.
38. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Bekhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-7.
39. Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant 1997;3:157-63.
40. Ruffini PA, Grodeland G, Fredriksen AB, Bogen B. Human chemokine MIP1alpha increases efficiency of targeted DNA fusion vaccines. Vaccine 2010;29:191-9.
41. van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 2010;9:503-17.